|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Risks of proteinuria and hypertension with bevacizumab,an antibody against vascu-lar endothelial growth factor:systematic review and meta-analysis显示文摘 | Zhu X Wu S Dahut WL | | 0，，02： | 1 |
| 2 | Risks of proteinuria and hy- pertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analy- sis 显示文摘 | Zhu X Wu S Dahut WL | 2007 | Am J Kidney Dis2007，49，2： | 1 |
| 3 | Randomized phase' ]/trial of docetaxel plus thalido- mide in androgen-independent prostate cancer显示文摘 | Dahut WL | 2004 | J Clin Oncol2004，22，3： | 1 |
| 4 | Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors 显示文摘 | Dahut WL Lakhani NJ Gulley JL | 2006 | Cancer Biol Ther2006，5，1： | 1 |
| 5 | Randomised phase Ⅱ trial of docetaxel plus thalidomide in androgen-independent prosrate cancer 显示文摘 | Dahut WL Gulley JL Arlen PM | 2004 | J Clin Oncol2004，22，13： | 1 |
| 6 | VEGF inhibitors and prostate cancer therapy显示文摘 | Aragon-Ching JB Dahut WL | 2009 | Curr Mol Pharmacol2009，2，2： | 1 |
| 7 | Determination of the antiangiogenesis agent 2-methoxyestradiol in human plasma by liquid chromatography with ultraviolet detection显示文摘 | Lakhani N J Sparreboom A Dahut WL | 2004 | J Chromatogr B Analyt Technol Biomed Life Sci2004，806，2： | 1 |
| 8 | Randomized phase Ⅱ trim of docetaxel plus thalidomide in androgen-independent prostate cancer显示文摘 | Dahut WL Gulley JL Arlen PM | 2004 | J Clin Oncol2004，22，13： | 1 |
| 9 | Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth fac- tor : systematic review and meta-analysis 显示文摘 | Zhu X Wu S Dahut WL | 2007 | Am J Kidney Dis2007，49，2： | 1 |
| 10 | Randomized Crossover Pharmacokinetic Studv of Solvent-based Paclitaxel and Nab - paclitaxel 显示文摘 | Gardner ER Dahut WL Scripture CD | 2008 | Clin Cancer Rea2008，14，13： | 1 |
| 11 | Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis 显示文摘 | Zhu XL Wu SH Dahut WL | 2007 | Am J Kidney D/s2007，49，2： | 1 |
| 12 | A phase Ⅱ clinical trial of sorafenib in androgen-independent prostate cancer显示文摘 | Dahut WL Scripture C Posadas E | 2008 | Clin Cancer Res2008，14，1： | 1 |
| 13 | Randomized phase II Trial of docetaxel plus thalidomide in androgen-inde- pendent prostate cancer 显示文摘 | DAHUT WL GULLEY JL ARLEN PM | 2004 | J Clin Oncol2004，22，13： | 1 |
| 14 | Randomized cross- over pharma - cokinetic study of solvent - based paclitaxel and nab - paclitaxel显示文摘 | Gardner ER Dahut WL Scripture CD | 2008 | Clin Cancer Res2008，14，13： | 1 |
| 15 | Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel显示文摘 | Gardner ER Dahut WL Scripture CD | 2008 | Clin Cancer Res2008，14，13： | 1 |
| 16 | Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and Pharmacological effects of thalidomide显示文摘 | Ando Y Price DK Dahut WL | 2002 | Cancer Biol Ther2002，1，6： | 1 |
| 17 | Randomized phaseⅡtrial of docetaxel plus thalidomide in androgen-independent prostate cancer显示文摘 | Dahut WL Gulley JL Arlen PM | 2004 | JClin Onco2004，22，13： | 1 |
| 18 | Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta--analysis 显示文摘 | Zhu X Wu S Dahut WL | 2007 | Am J Kidney Dia2007，49，2： | 1 |
| 19 | Phase I clinical trial of oral 2-methoxyestradiol,an antiangiogenie and apoptotie agent,in patients with solid tumor显示文摘 | Dahut WL Lakhani NJ Gulley JL | 2006 | Cancer Biol Ther2006，5，1： | 1 |
| 20 | Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis显示文摘 | Zhu XL Wu SH Dahut WL | 2007 | Am 3Kidney Dis2007，49，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员